Aptamer Group and AstraZeneca Announce siRNA Delivery Collaboration

Aptamer Group and AstraZeneca have announced a strategic collaboration following promising initial results with Aptamer's fibrotic liver delivery vehicles. 

The partnership will focus on addressing the challenges of precise siRNA delivery, with the hope of revolutionizing therapeutic applications with Aptamer’s Optimer® technology, which provides affinity ligand design, quality and supply. As part of the partnership, AstraZeneca will supply siRNA whilst Aptamer will perform in-house testing using their Optimer-based delivery system, and if successful, the partnership will advance to animal model testing to demonstrate efficacy. 

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA.

Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA.

Under the agreement, AstraZeneca will provide an siRNA to be trialled with Aptamer’s Optimer-based delivery vehicle for fibrotic liver cells. Aptamer Group will conduct in-house experimental work to assess the effectiveness of this delivery vehicle with the AstraZeneca’s siRNA. Upon success, Aptamer Group will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca.

Delivery of siRNA to precise cell types and tissues with successful cell internalisation remains a significant challenge for the wider therapeutic application of the technology. Despite this limitation, the siRNA market was still valued at over $13 billion in 2023. Optimer technology could represent a paradigm shift in the targeted delivery of siRNA molecules, due to the high levels of selectivity, high affinity and simple conjugation of siRNA payloads, offered using Optimer delivery systems as non-viral vectors. If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods.

For more, please find the original story source here.